Literature DB >> 17890461

Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation.

Bethan Freestone1, Aun Yeong Chong, Sarah Nuttall, Andrew D Blann, Gregory Y H Lip.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is associated with a prothrombotic state, which is related to endothelial damage/dysfunction. Plasma levels of soluble E-selectin (sE-sel), von Willebrand factor (vWf), and soluble thrombomodulin (sTM) have been used as indexes of endothelial activation, damage/dysfunction, and endothelial damage, respectively. Nitric oxide is also made by a healthy endothelium, and a total body nitrate/nitrite product (NOx) is used as a measure of endothelial nitric oxide production. We hypothesized that the levels of these markers of endothelial function would be abnormal in patients with paroxysmal, persistent, and permanent AF.
METHODS: We studied 145 AF patients (paroxysmal AF, 35 patients; permanent AF, 50 patients; persistent AF, 60 patients) and 35 patients with "lone" AF. Plasma levels of sE-sel, vWf, and sTM (measured by enzyme-linked immunosorbent assay) and NOx (measured by a colorimetric assay based on the Griess reaction) were compared to 40 age-matched healthy control subjects in sinus rhythm.
RESULTS: Patients with AF had significantly higher plasma levels of vWf (p < 0.001) and sE-sel (p = 0.005) compared with control subjects, but sTM and NOx levels were not significantly different. Levels did not differ significantly among the clinical subgroups of patients with paroxysmal, persistent, and permanent AF. Patients with lone AF had significantly higher vWF levels (p = 0.003) and significantly lower sTM levels (p = 0.0361) compared to control subjects, but sE-sel and NOx levels were not significantly different. There were no significant differences in the AF study population in vWF, sE-sel or sTM levels after 4 weeks of warfarin treatment.
CONCLUSION: Endothelial perturbation exists in all clinical subgroups of patients with AF, including those with lone AF, which may contribute to the prothrombotic state seen in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890461     DOI: 10.1378/chest.07-1185

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women.

Authors:  David Conen; Paul M Ridker; Brendan M Everett; Usha B Tedrow; Lynda Rose; Nancy R Cook; Julie E Buring; Christine M Albert
Journal:  Eur Heart J       Date:  2010-05-25       Impact factor: 29.983

2.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 3.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

4.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

5.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

6.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31

Review 8.  Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation.

Authors:  Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  J Atr Fibrillation       Date:  2014-10-31

9.  The determinants of stroke phenotypes were different from the predictors (CHADS2 and CHA2DS2-VASc) of stroke in patients with atrial fibrillation: a comprehensive approach.

Authors:  Semi Oh; Suk Jae Kim; Soo-Kyoung Ryu; Gyeong-Moon Kim; Chin Sang Chung; Kwang Ho Lee; Oh Young Bang
Journal:  BMC Neurol       Date:  2011-08-24       Impact factor: 2.474

10.  Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).

Authors:  Eun-Jeong Kim; Xiaoyan Yin; João D Fontes; Jared W Magnani; Steve A Lubitz; David D McManus; Sudha Seshadri; Ramachandran S Vasan; Patrick T Ellinor; Martin G Larson; Emelia J Benjamin; Michiel Rienstra
Journal:  Am Heart J       Date:  2016-04-30       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.